Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03790852 · ClinicalTrials.gov registry record · Phase 1
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
A Phase 1 study, sponsored by Kodiak Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT03790852 is a Phase 1 study that was terminated before completion, run by Kodiak Sciences. The registered enrollment target is 121 participants.
The verdict
NCT03790852, a Phase 1 study, was terminated before completion, sponsored by Kodiak Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
Interventions
- DRUG KSI-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-12-26 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03790852
The ClinicalTrials.gov registry entry for NCT03790852 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kodiak Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KSI-301 is the first listed.
NCT03790852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03790852 about?
NCT03790852 is a clinical study titled "Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO". This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
What is the current status of trial NCT03790852?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2018-12-26. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT03790852?
The interventions under investigation include: KSI-301 (DRUG).
Who is sponsoring clinical trial NCT03790852?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.